Shubha Deep Roy, MD
Cardiovascular Disease · Des Moines, IANPI 1689061095
Payments from drug & device makers
What this record shows
22 manufacturers reported payments, led by Abbott at 48.9% of the total. Reporting peaked in 2022 at $4,161 and has fallen 84.7% since, to $637 in 2025. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $80.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Edwards Lifesciences$1K
- Medtronic$1K
- Abiomed$352
- Shockwave Medical, Inc$241
- Inari Medical, Inc.$235
- plus $1K from 16 others
What the payments were for
- Travel & lodging$4,82752%
- Food & beverage$4,47148%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 41 | $4,551 |
| Edwards Lifesciences | 9 | $1,468 |
| Medtronic | 13 | $1,360 |
| Abiomed | 7 | $352 |
| Shockwave Medical, Inc | 4 | $241 |
| Inari Medical, Inc. | 4 | $235 |
| Boston Scientific | 10 | $223 |
| Teleflex LLC | 4 | $201 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Novartis | 4 | $101 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $84 |
| Boehringer Ingelheim | 1 | $74 |
| Getinge USA Sales, LLC | 2 | $36 |
| Stryker | 2 | $31 |
| Chiesi USA, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Heartflow, Inc. | 1 | $17 |
| Cvrx, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,875
- OMNILINK ELITE$1,262
- COREVALVE EVOLUT R$883
- Edwards SAPIEN 3 Transcatheter Heart Valve$653
- CardioMEMS HF System$202
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$201
- COROFLOW$169
- TURNPIKE$148
- JETi Peripheral Catheter$142
- Impella$137
- FLOWTRIEVER CATHETER, S$132
- CT THROMBECTOMY SYSTEM KIT$132
- Diamondback Coronary$124
How this compares
$9,298 in reported general payments places this provider in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $231,561 |
| FarxigaDapagliflozin Propanediol | 164 | $119,561 |
| XareltoRivaroxaban | 98 | $94,185 |
| EntrestoSacubitril/Valsartan | 80 | $74,751 |
| JardianceEmpagliflozin | 85 | $72,055 |
| BrilintaTicagrelor | 30 | $23,345 |
| Praluent PenAlirocumab | 13 | $9,040 |
| Metoprolol Succinate | 454 | $3,658 |
| Atorvastatin Calcium | 313 | $2,430 |
| ClopidogrelClopidogrel Bisulfate | 302 | $1,958 |
| Dilt-XrDiltiazem Hcl | 59 | $1,585 |
| Bumetanide | 59 | $1,173 |
| Potassium Chloride | 37 | $1,166 |
| Losartan Potassium | 167 | $1,153 |
| Propafenone Hcl | 11 | $1,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $231,561234 claims |
| AstraZenecaFarxiga, Brilinta | $16 | $142,906194 claims |
| NovartisEntresto | $101 | $74,75180 claims |
| Boehringer IngelheimJardiance | $74 | $72,05585 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Des Moines
- Craig StarkDes Moines$28K
- Nelson Telles GarciaDes Moines$7K
- Wafic ItaniDes Moines$5K
- Marc KleinDes Moines$5K
- Eduardo AntezanoDes Moines$4K
- Muhammad AwanDes Moines$4K
- Gardar SigurdssonDes Moines$2K
- Ratna GangiDes Moines$2K
- Deepika AbbadiDes Moines$2K
- Abdul ChughtaiDes Moines$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.